Cooper C L, Malik K U
J Pharmacol Exp Ther. 1984 Apr;229(1):139-47.
We have investigated the mechanism of action of arginine vasopressin (AVP) on vascular tone and renal output of prostaglandins (PGs) by examining the effect of Ca++ depletion, Ca++ antagonists and calmodulin inhibitors in the isolated Tyrode perfused rat kidney. Administration of AVP (0.027-0.27 nmol) into the kidney produced a dose-related renal vasoconstriction and an increase in the output of PGE2 and 6-keto-PGF1 alpha, the stable hydrolysis product of PGI2. Omission of Ca++ (1.8 mM) or addition of Ca++ channel blockers, diltiazem (6.0 X 10(-5) M) or nimodipine (4.7 X 10(-5) M), to the perfusion fluid attenuated the renal vasoconstriction, but not the output of PGs elicited by AVP. Infusion of intracellular Ca++ antagonists, Dantrium (3.1 X 10(-5) M), TMB-8 (2.3 X 10(-6) M) or ryanodine (2 X 10(-6) M) or calmodulin inhibitors, trifluoperazine (2 X 10(-6) M) or W-7 (2 X 10(-6) M), abolished the rise in renal output of PGs produced by AVP during Ca++ depletion. Calmodulin inhibitors, which inhibited the AVP-induced release of PGs in the presence of Ca++, failed to alter the renal vasoconstrictor effect of the peptide. Administration of d(CH2)5Tyr(Me)AVP, a selective antagonist of pressor actions of AVP, abolished the renal vasoconstrictor response and release of PGs elicited by AVP. In contrast, d(CH2)5-D-ValVAVP, an antagonist of antidiuretic and to a lesser extent of pressor actions of AVP, failed to alter the renal vasoconstrictor response but attenuated the output of PGs produced by AVP. AVP antagonists did not alter the effect of angiotensin II (0.096 nmol) to cause renal vasoconstriction and enhance PG output.(ABSTRACT TRUNCATED AT 250 WORDS)
我们通过研究在分离的用台氏液灌注的大鼠肾脏中钙离子耗竭、钙离子拮抗剂和钙调蛋白抑制剂的作用,来探究精氨酸加压素(AVP)对血管张力和前列腺素(PGs)肾输出量的作用机制。向肾脏注射AVP(0.027 - 0.27纳摩尔)会产生剂量相关的肾血管收缩,并使PGE2和6-酮-PGF1α(PGI2的稳定水解产物)的输出量增加。从灌注液中去除钙离子(1.8毫摩尔)或添加钙离子通道阻滞剂地尔硫䓬(6.0×10⁻⁵摩尔)或尼莫地平(4.7×10⁻⁵摩尔)会减弱肾血管收缩,但不会减弱AVP引起的PGs输出。输注细胞内钙离子拮抗剂丹曲林(3.1×10⁻⁵摩尔)、TMB - 8(2.3×10⁻⁶摩尔)或ryanodine(2×10⁻⁶摩尔)或钙调蛋白抑制剂三氟拉嗪(2×10⁻⁶摩尔)或W - 7(2×10⁻⁶摩尔)会消除钙离子耗竭期间AVP引起的PGs肾输出量增加。在有钙离子存在时抑制AVP诱导的PGs释放的钙调蛋白抑制剂,未能改变该肽的肾血管收缩作用。注射AVP升压作用的选择性拮抗剂d(CH2)5Tyr(Me)AVP,可消除AVP引起的肾血管收缩反应和PGs释放。相反,AVP抗利尿作用且在较小程度上抗升压作用的拮抗剂d(CH2)5 - D - ValVAVP,未能改变肾血管收缩反应,但减弱了AVP产生的PGs输出。AVP拮抗剂未改变血管紧张素II(0.096纳摩尔)引起肾血管收缩和增强PG输出的作用。(摘要截断于250字)